BioVie Inc. (BIVI)
- Previous Close
0.4884 - Open
0.5050 - Bid 0.3500 x 200
- Ask 0.6277 x 200
- Day's Range
0.4800 - 0.5050 - 52 Week Range
0.4450 - 8.6900 - Volume
489,751 - Avg. Volume
2,614,254 - Market Cap (intraday)
26.721M - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1700 - Earnings Date Apr 19, 2024 - Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
bioviepharma.comRecent News: BIVI
Performance Overview: BIVI
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIVI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIVI
Valuation Measures
Market Cap
26.83M
Enterprise Value
16.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.58
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.43
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.82%
Return on Equity (ttm)
-257.84%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-43.27M
Diluted EPS (ttm)
-1.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
20.23M
Total Debt/Equity (mrq)
136.98%
Levered Free Cash Flow (ttm)
-29.67M
Research Analysis: BIVI
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell